Evidence map›Paper›PMID 31719636›Full record

ArticleScientific reports2019

Insulin enhancement of the antitumor activity of chemotherapeutic agents in colorectal cancer is linked with downregulating PIK3CA and GRB2.

Siddarth Agrawal, Marta Woźniak, Mateusz Łuc, Sebastian Makuch, Ewa Pielka, Anil Kumar Agrawal, Joanna Wietrzyk, Joanna Banach, Andrzej Gamian, Monika Pizon and 1 more

Abstract read
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Siddarth AgrawalDepartment of Pathology, Wroclaw Medical University, Wroclaw, Poland. siddarth@agrawal.pl.
Marta WoźniakDepartment of Pathology, Wroclaw Medical University, Wroclaw, Poland.
Mateusz ŁucDepartment of Pathology, Wroclaw Medical University, Wroclaw, Poland.
Sebastian MakuchDepartment of Pathology, Wroclaw Medical University, Wroclaw, Poland.
Ewa PielkaDepartment of Pathology, Wroclaw Medical University, Wroclaw, Poland.
Anil Kumar Agrawal2nd Department and Clinic of General and Oncological Surgery, Wroclaw Medical University, Wroclaw, Poland.
Joanna WietrzykDepartment of Experimental Oncology, Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland.ORCID http://orcid.org/0000-0003-4980-6606
Joanna BanachDepartment of Experimental Oncology, Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland.
Andrzej GamianDepartment of Biochemistry, Wroclaw Medical University, Wroclaw, Poland.
Monika PizonTransfusion Center Bayreuth, Kurpromenade 2, 95448, Bayreuth, Germany.
Piotr ZiółkowskiDepartment of Pathology, Wroclaw Medical University, Wroclaw, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The present state of cancer chemotherapy is unsatisfactory. New anticancer drugs that marginally improve the survival of patients continue to be developed at an unsustainably high cost. The study aimed to elucidate the effects of insulin (INS), an inexpensive drug with a convincing safety profile, on the susceptibility of colon cancer to chemotherapeutic agents: 5-fluorouracil (FU), oxaliplatin (OXA), irinotecan (IRI), cyclophosphamide (CPA) and docetaxel (DOC). To examine the effects of insulin on cell viability and apoptosis, we performed an in vitro analysis on colon cancer cell lines Caco-2 and SW480. To verify the results, we performed in vivo analysis on mice bearing MC38 colon tumors. To assess the underlying mechanism of the therapy, we examined the mRNA expression of pathways related to the signaling downstream of insulin receptors (INSR). Moreover, we performed Western blotting to confirm expression patterns derived from the genetic analysis. For the quantification of circulating tumor cells in the peripheral blood, we used the maintrac method. The results of our study show that insulin-pretreated colon cancer cells are significantly more susceptible to commonly used chemotherapeutics. The apoptosis ratio was also enhanced when INS was administered complementary to the examined drugs. The in vivo study showed that the combination of INS and FU resulted in significant inhibition of tumor growth and reduction of the number of circulating tumor cells. This combination caused a significant downregulation of the key signaling substrates downstream of INSR. The results indicate that the downregulation of PIK3CA (phosphatidylinositol 3-kinase catalytic subunit alpha), which plays a critical role in cell signaling and GRB2 (growth factor receptor-bound protein 2), a regulator of cell proliferation and differentiation may be responsible for the sensitizing effect of INS. These findings were confirmed at protein levels by Western blotting. In conclusion, these results suggest that INS might be potentially applied to clinical use to enhance the therapeutic effectiveness of chemotherapeutic drugs. The findings may become a platform for the future development of new and inexpensive strategies for the clinical chemotherapy of tumors.

Indexed as

AnimalsAntineoplastic AgentsBlotting, WesternCaco-2 CellsCell Line, TumorClass I Phosphatidylinositol 3-KinasesColorectal NeoplasmsCyclophosphamideDocetaxelDown-RegulationDrug SynergismFemaleFluorouracilGRB2 Adaptor ProteinHumansInsulinAntineoplastic AgentsClass I Phosphatidylinositol 3-KinasesCyclophosphamideDocetaxelFluorouracilGRB2 Adaptor ProteinGRB2 protein, humanInsulinIrinotecanOxaliplatinPIK3CA protein, human

Identifiers

PMID31719636
PMCPMC6851401

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.